Molecular engineering of a small trypsin inhibitor based on the binding loop of horsegram seed Bowman-Birk inhibitor

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 4, 2011, Pages 553-560

  Muricken, Deepa G ^a   Gowda, Lalitha R ^a  

^a CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

Author keywords

Bioavailability; Dolichos biflorus; Protein expression; Recombinant trypsin inhibitor domain; Trypsin tryptase inhibition

Indexed keywords

BOWMAN BIRK INHIBITOR; RECOMBINANT TRYPSIN INHIBITOR DOMAIN; TRYPSIN INHIBITOR; TRYPTASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOLICHOS; DRUG PENETRATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; ESCHERICHIA COLI; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BINDING SITES; CATTLE; CLONING, MOLECULAR; DISULFIDES; HUMANS; KINETICS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPSIN; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS; TRYPTASES;

ANIMALIA; BOVINAE; DOLICHOS BIFLORUS; MACROTYLOMA UNIFLORUM;

EID: 79959906198     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2010.536158     Document Type: Article

References (46)

1. Steiner RF. The interaction of the Bowman-Birk inhibitor with trypsin and chymotrypsin. Eur J Biochem 1972;27:87-92.
2. Galasso I, Piergiovanni AR, Lioi L, Campion B, Bollini R, Sparvoli F. Genome organization of Bowman-Birk inhibitor in common bean (Phaseolus vulgaris L.)Mol Breeding 2009;23:617-624.
3. Chen P, Rose J, Love R, Wei CH, Wang BC. Reactive sites of an anticarcinogenic Bowman-Birk proteinase inhibitor are similar to other trypsin inhibitors. J Biol Chem 1992;267:1990-1994.
4. Terada S, Sato K, Kato T, Izumiya N. Inhibitory properties of nonapeptide loop structures related to reactive sites of soybean Bowman-Birk inhibitor. FEBS Lett 1978;90:89-92. (Pubitemid 8355529)
5. Odani S, Ikenaka T. Scission of soybean Bowman-Birk proteinase inhibitor into two small fragments having either trypsin or chymotrypsin inhibitory activity. J Biochem (Tokyo). 1973;74:697-715.
6. Luckett S, Garcia RS, Barker JJ, Konarev AV, Shewry PR, Clarke AR et al. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J Mol Biol 1999;290:525-533. (Pubitemid 29324836)
7. Bode W, Huber R. Structural basis of the endoproteinase-protein inhibitor interaction. Biochim Biophys Acta 2000;1477:241-252. (Pubitemid 30119904)
8. Qi RF, Song ZW, Chi CW. Structural features and molecular evolution of Bowman-Birk protease inhibitors and their potential application. Acta Biochim Biophys Sin (Shanghai) 2005;37:283-292.
9. Barbosa JA, Silva LP, Teles RC, Esteves GF, Azevedo RB, Ventura MM et al. Crystal structure of the Bowman-Birk Inhibitor from Vigna unguiculata seeds in complex with beta-trypsin at 1.55 A resolution and its structural properties in association with proteinases. Biophys J 2007;92:1638-1650. (Pubitemid 46393475)
10. Capaldi S, Perduca M, Faggion B, Carrizo ME, Tava A, Ragona L et al. Crystal structure of the anticarcinogenic Bowman-Birk inhibitor from snail medic (Medicago scutellata) seeds complexed with bovine trypsin. J Struct Biol 2007;158:71-79. (Pubitemid 46441893)
11. Catalano M, Ragona L, Molinari H, Tava A, Zetta L. Anticarcinogenic Bowman Birk inhibitor isolated from snail medic seeds (Medicago scutellata): solution structure and analysis of self-association behavior. Biochemistry 2003;42:2836-2846. (Pubitemid 36331527)
12. Koepke J, Ermler U, Warkentin E, Wenzl G, Flecker P. Crystal structure of cancer chemopreventive Bowman-Birk inhibitor in ternary complex with bovine trypsin at 2.3 A resolution. Structural basis of Janus-faced serine protease inhibitor specificity. J Mol Biol 2000;298:477-491.
13. Li Y, Huang Q, Zhang S, Liu S, Chi C, Tang Y. Studies on an artificial trypsin inhibitor peptide derived from the mung bean trypsin inhibitor: chemical synthesis, refolding, and crystallographic analysis of its complex with trypsin. J Biochem 1994;116: 18-25. (Pubitemid 24230777)
14. Lin G, Bode W, Huber R, Chi C, Engh RA. The 0.25-nm X-ray structure of the Bowman-Birk-type inhibitor from mung bean in ternary complex with porcine trypsin. Eur J Biochem 1993;212: 549-555. (Pubitemid 23076124)
15. Park EY, Kim JA, Kim HW, Kim YS, Song HK. Crystal structure of the Bowman-Birk inhibitor from barley seeds in ternary complex with porcine trypsin. J Mol Biol 2004;343:173-186. (Pubitemid 39277456)
16. Tsunogae Y, Tanaka I, Yamane T, Kikkawa J, Ashida T, Ishikawa C et al. Structure of the trypsin-binding domain of Bowman-Birk type protease inhibitor and its interaction with trypsin. J Biochem 1986;100:1637-1646. (Pubitemid 17213626)
17. Kennedy AR. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 1998;68:1406S-1412S. (Pubitemid 28550921)
18. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 1997;344:133-138. (Pubitemid 27328105)
19. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF. Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor. Biokhimiia 1993;58:1437-1444.
20. Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci 2008;53: 175-180. (Pubitemid 350265667)
21. Murthy HM, Judge K, DeLucas L, Padmanabhan R. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J Mol Biol 2000;301:759-767.
22. Caccialupi P, Ceci LR, Siciliano RA, Pignone D, Clemente A, Sonnante G. Bowman-Birk Inhibitors in Lentil: Heterologous Expression, Functional Characterisation and anti-proliferative Properties in Human Colon Cancer Cells. Food Chemistry 2010;120:1058-1066.
23. Joanitti GA, Azevedo RB, Freitas SM. Apoptosis and lysosome membrane permeabilization induction on breast cancer cells by an anticarcinogenic Bowman-Birk protease inhibitor from Vigna unguiculata seeds. Cancer Lett 2010;293:73-81.
24. Clemente A, Moreno FJ, Marín-Manzano Mdel C, Jiménez E, Domoney C. The cytotoxic effect of Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases. Mol Nutr Food Res 2010;54:396-405.
25. Lanza A, Tava A, Catalano M, Ragona L, Singuaroli I, Robustelli della Cuna FS et al. Effects of the Medicago scutellata trypsin inhibitor (MsTI) on cisplatin-induced cytotoxicity in human breast and cervical cancer cells. Anticancer Res 2004;24:227-233. (Pubitemid 38279712)
26. Birk Y. The Bowman-Birk inhibitor. Trypsin- and chymotrypsininhibitor from soybeans. Int J Pept Protein Res 1985;25:113-131.
27. Yavelow J, Finlay TH, Kennedy AR, Troll W. Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res 1983;43:2454s-2459s.
28. Blanca HL, Hsieh CC, Lumen BO. Lunasin and Bowman-Birk protease inhibitor (BBI) in US commercial soy foods. Food Chem 2009;115:574-580.
29. Billings PC, St Clair WH, Maki PA, Kennedy AR. Distribution of the Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett 1992;62:191-197.
30. Fernandez JH, Mello MO, Galgaro L, Tanaka AS, Silva-Filho MC, Neshich G. Proteinase inhibition using small Bowman-Birk-type structures. Genet Mol Res 2007;6:846-858. (Pubitemid 350292798)
31. Jaulent AsM, Leatherbarrow RJ. Design, synthesis and analysis of novel bicyclic and bifunctional protease inhibitors. Protein Eng Des Sel 2004;17:681-687. (Pubitemid 40601888)
32. Scarpi D, McBride JD, Leatherbarrow RJ. Inhibition of human beta-tryptase by Bowman-Birk inhibitor derived peptides: creation of a new tri-functional inhibitor. Bioorg Med Chem 2004;12:6045-6052. (Pubitemid 39440445)
33. Zablotna E, Jaskiewicz A, Legowska A, Miecznikowska H, Lesner A, Rolka K. Design of serine proteinase inhibitors by combinatorial chemistry using trypsin inhibitor SFTI-1 as a starting structure. J Pept Sci 2007;13:749-755. (Pubitemid 350081529)
34. Sreerama YN, Das JR, Rao DR, Gowda LR. Double-headed trypsin/ chymotrypsin inhibitors from horse gram (Dolichos biflorus): purification, molecular and kinetic properties. J Food Biochem 1997;21:461-477. (Pubitemid 127362854)
35. Muricken DG, Gowda LR. Functional expression of Horsegram (Dolichos biflorus) Bowman-Birk inhibitor and its self association. Biochim Biophys Acta 2010;1804:1413-1423.
36. Kakade ML, Simons N, Liener IE. An evolution of natural vs. synthetic substrate for measuring the antitryptic activity of soybean samples. Cereal Chem 1969;46:518-526.
37. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
38. Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc 1934;56:658-666.
39. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953;55:170-171.
40. Fear G, Komarnytsky S, Raskin I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol Ther 2007;113:354-368. (Pubitemid 46149049)
41. McBride JD, Leatherbarrow RJ. Synthetic peptide mimics of the Bowman-Birk inhibitor protein. Curr Med Chem 2001;8:909-917. (Pubitemid 32633549)
42. Prakash B, Selvaraj S, Murthy MR, Sreerama YN, Rao DR, Gowda LR. Analysis of the amino acid sequences of plant Bowman-Birk inhibitors. J Mol Evol 1996;42:560-569. (Pubitemid 26197146)
43. Qi RF, Liu ZX, Xu SQ, Zhang L, Shao XX, Chi CW. Small peptides derived from the Lys active fragment of the mung bean trypsin inhibitor are fully active against trypsin. Febs J 2010;277:224-232.
44. Stubbs MT, Morenweiser R, Stürzebecher J, Bauer M, Bode W, Huber R et al. The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin. Implications for the structure of human mast cell tryptase and its inhibition. J Biol Chem 1997;272:19931-19937. (Pubitemid 27340093)
45. Sommerhoff CP, Söllner C, Mentele R, Piechottka GP, Auerswald EA, Fritz H. A Kazal-type inhibitor of human mast cell tryptase: isolation from the medical leech Hirudo medicinalis, characterization, and sequence analysis. Biol Chem Hoppe-Seyler 1994;375:685-694.
46. Marín-Manzano MC, Ruiz R, Jiménez E, Rubio LA, Clemente A. Anti-carcinogenic soyabean Bowman-Birk inhibitors survive faecal fermentation in their active form and do not affect the microbiota composition in vitro. Br J Nutr 2009;101:967-971.